Chinese and Western Integrative Medicine for Stage IIIb-IVb Non-Small Cell Lung Cancer: Design and Rationale of a Multi-center, Prospective Registry (NSCLC-Chinese and Western Integrative Medicine cohort)

Introduction:This planned multicenter observational study will evaluate the overall survival of those undergoing integrated Chinese and Western medicine for stage IIIb-IVb non-small cell lung cancer and analyze the factors related to the prognosis. Method and Analysis:The prospective cohort will enroll patients with stage IIIb-IVb NSCLC from March 1, 2019, to December 31, 2025, and follow them for 5 years. We plan to collect data on the patients' demographics, treatment, overall survival, and factors related to the prognosis. Ethics and Dissemination:The institutional review board and ethics committee reviewed the study protocol. All patients will provide informed consent before enrollment.Trial registration number: ChiCTR1900021430

Automated summary

This planned multicenter observational study aims to assess the overall survival rate of patients with stage IIIb-IVb non-small cell lung cancer receiving integrated Chinese and Western medicine, and analyze the factors related to prognosis. The study will enroll patients from March 1, 2019 to December 31, 2025 and follow them for 5 years. Data on demographics, treatment, overall survival, and prognostic factors will be collected. The study protocol has been reviewed by the institutional review board and ethics committee, and informed consent will be obtained from all patients before enrollment. Trial registration number: ChiCTR1900021430.